Eurofins Scientific SE (ERFSF)
48.89
-2.94
(-5.68%)
USD |
OTCM |
Dec 16, 15:51
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 9.163B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -13.38% |
| Valuation | |
| PE Ratio | 23.40 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.326 |
| Price to Book Value | 1.630 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.5374 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5592 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 67.67% |
Profile
| Eurofins, headquartered in Luxembourg, has three main business lines: food and environment testing, services to pharmaceutical and biotechnology companies, and clinical diagnostics. Through its subsidiaries, Eurofins provides various analytical testing and laboratory services on a global scale, and the company offers testing options for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products. The company also has a growing clinical diagnostics unit, with specialties in infectious diseases, prenatal screening, and organ transfer. Eurofins operates over 900 laboratories in 54 countries. |
| URL | https://www.eurofins.com |
| Investor Relations URL | https://www.eurofins.com/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Jul. 24, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 03, 2024 |
Ratings
Profile
| Eurofins, headquartered in Luxembourg, has three main business lines: food and environment testing, services to pharmaceutical and biotechnology companies, and clinical diagnostics. Through its subsidiaries, Eurofins provides various analytical testing and laboratory services on a global scale, and the company offers testing options for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products. The company also has a growing clinical diagnostics unit, with specialties in infectious diseases, prenatal screening, and organ transfer. Eurofins operates over 900 laboratories in 54 countries. |
| URL | https://www.eurofins.com |
| Investor Relations URL | https://www.eurofins.com/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Jul. 24, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 03, 2024 |